13D Filing: Celgene Corp /de/ and Alliqua Biomedical Inc. (NASDAQ:ALQA)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

 

Under the Securities Exchange Act of
1934
(Amendment No. 6)*

 

Alliqua BioMedical, Inc.

(Name of Issuer)

  

Common Stock, $0.001 par value

(Title of Class of Securities)

 

019621200

(CUSIP Number)

 

Mark J. Alles Chief Executive Officer Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 (908) 673-9000

(Name, Address and Telephone Number
of Person Authorized to Receive Notices and Communications)

March 27, 2017

(Date of Event Which Requires Filing
of this Statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box: ¨

 

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).